Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Miraculins and Cachet Sign LOI for China Rights to Diabetes Test

publication date: Oct 15, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Miraculins, a Canadian maker of non-invasive diagnostic tests, has signed a Letter of Intent to sell China rights for a diabetes test to Cachet Pharma, a China drug distributor. Miraculins acquired rights to the SCOUT DS® technology less than two months ago. SCOUT is a non-invasive test that measures changes in a person’s skin to indicate prediabetes and diabetes type 2. More details....

Stock Symbols: (TSX-V: MOM) (SHE: 002462)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors